Research And Markets Research And Markets
0 CHECKOUT

Left Ventricular Dysfunction - Pipeline Review, H1 2015

  • ID: 3112090
  • January 2015
  • 57 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Amgen Inc.
  • Innopharmax Inc.
  • RedHill Biopharma Ltd.
  • MORE

Left Ventricular Dysfunction - Pipeline Review, H1 2015

Summary

This, ‘Left Ventricular Dysfunction - Pipeline Review, H1 2015’, provides an overview of the Left Ventricular Dysfunction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Amgen Inc.
  • Innopharmax Inc.
  • RedHill Biopharma Ltd.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Left Ventricular Dysfunction Overview
Therapeutics Development
Pipeline Products for Left Ventricular Dysfunction - Overview
Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis
Left Ventricular Dysfunction - Therapeutics under Development by Companies
Left Ventricular Dysfunction - Therapeutics under Investigation by Universities/Institutes
Left Ventricular Dysfunction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Left Ventricular Dysfunction - Products under Development by Companies
Left Ventricular Dysfunction - Products under Investigation by Universities/Institutes
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Amgen Inc.
Innopharmax Inc.
RedHill Biopharma Ltd.
Left Ventricular Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CAP-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carvedilol CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carvedilol CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cimaglermin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omecamtiv mecarbil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target O2 Radical for Left Ventricular Dysfunction and Diabetic Complications - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Left Ventricular Dysfunction - Recent Pipeline Updates
Left Ventricular Dysfunction - Dormant Projects
Left Ventricular Dysfunction - Discontinued Products
Left Ventricular Dysfunction - Product Development Milestones
Featured News & Press Releases
Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013
Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013
Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Left Ventricular Dysfunction, H1 2015
Number of Products under Development for Left Ventricular Dysfunction - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Left Ventricular Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2015
Left Ventricular Dysfunction - Pipeline by Amgen Inc., H1 2015
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H1 2015
Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Left Ventricular Dysfunction Therapeutics - Recent Pipeline Updates, H1 2015
Left Ventricular Dysfunction - Dormant Projects, H1 2015
Left Ventricular Dysfunction - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Left Ventricular Dysfunction, H1 2015
Number of Products under Development for Left Ventricular Dysfunction - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Acorda Therapeutics, Inc.
Amgen Inc.
Innopharmax Inc.
RedHill Biopharma Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db